ERAS

8-K - Erasca, Inc. (0001761918) (Filer)

4 - Erasca, Inc. (0001761918) (Issuer)

144 - Erasca, Inc. (0001761918) (Subject)

10-K - Erasca, Inc. (0001761918) (Filer)

8-K - Erasca, Inc. (0001761918) (Filer)

Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for

Worldwide rights position Erasca to advance ERAS-0015 through a unified global development strategy ERAS-0015's promising early clinical data underscore its potential to be a best-in-class RAS-targeting agent Initial Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the exercise of its option to expand the existing license agreement with Joyo Pharmatech Co., Ltd. (Joyo) to include China, Hong Kong, and Macau, which will

4 - Erasca, Inc. (0001761918) (Issuer)

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (NASDAQ:TNGX, "Tango")) to evaluate Erasca's pan-RAS molecular glue, ERAS-0015, with Tango's PRMT5 inhibitor, vopimetostat (TNG462). "We've disclosed encoura

144 - Erasca, Inc. (0001761918) (Subject)

The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled "Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof." The paten

VANCOUVER, British Columbia, Feb. 17, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The FDA's accelerated approval framework continues to deliver measurable population health gains, with a January 2026 analysis in Cancer Research Communications confirming that drugs cleared through the program improved real-world progression-free survival in 65% of solid tumor indications studied, with none performing worse than the existing standard of care[1]. That track record is fueling a concentrated push among clinical-stage oncology companies toward registration-directed study designs in high-unmet-need tumor types, as demonstrated by Oncolytics Biotech Inc. (NASDAQ:ONCY), Incyte (NASD

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in February 2026 and will also participate in one-on-one investor meetings at each of these conferences. Guggenheim Emerging Outlook: Biotech Summit 2026 (February 11-12, 2026) Location: New York, NY Format: Fireside Chat Date and Time: Thursday, February 12, 1:00 pm Eastern Time Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25-26, 202

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

4 - Erasca, Inc. (0001761918) (Issuer)

8-K - Erasca, Inc. (0001761918) (Filer)

Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares. The shares of common stock were sold to the public at a price of $10.00 per share. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other off

8-K - Erasca, Inc. (0001761918) (Filer)

424B5 - Erasca, Inc. (0001761918) (Filer)

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $225.0 million.

8-K - Erasca, Inc. (0001761918) (Filer)